Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

EU warns not enough COVID vaccines for all in Europe until 2022

10/27/2020 | 11:36am EST
FILE PHOTO: A woman holds a small bottle labeled with a

BRUSSELS (Reuters) - Only part of the European Union population can be inoculated against the new coronavirus before 2022, EU officials said in an internal meeting, as the vaccines the bloc is securing may not prove effective or may not be manufactured in sufficient doses.

The 27-nation bloc, with a population of 450 million, has booked more than 1 billion doses of potential COVID-19 vaccines from three drugmakers. It is negotiating the advance purchase of another billion vials with other companies.

"There will not be sufficient doses of COVID-19 vaccines for the entire population before the end of 2021," a European Commission official told diplomats from EU states in a closed-door meeting on Monday, a person who attended it told Reuters.

A second official confirmed the statement. An EU Commission spokesman was not immediately available for comment.

The EU Commission had earlier said vaccines will be limited "during the initial stages of deployment" but had never clarified how long the initial phase would last.

There is still no effective COVID-19 vaccine, but the first shots could be available at the beginning of next year, the Commission said earlier in October.

Given a likely limited supply, the Commission has for months urged EU governments to devise vaccination plans that would prioritise vulnerable and essential groups, such as healthcare workers, the elderly or people with chronic diseases.

But apart from a consensus on inoculating doctors and nurses, "there is no common line on other groups," the Commission official said at the internal meeting this week.

In July a paper agreed by the Commission and EU governments said at least 40% of the EU population should be vaccinated in the first phase.

Some EU countries want to book doses for their entire population with the aim of rolling them out already by mid-2021.

A third EU official said this bold goal could be achieved if the EU reached supply deals with at least seven vaccine candidates.

The EU has so far secured doses of the potential vaccines being developed by AstraZeneca, Sanofi and Johnson & Johnson. It has also said it is in talks with Moderna, Pfizer and CureVac.

(Reporting by Francesco Guarascio @fraguarascio, Editing by William Maclean and Alexandra Hudson)

By Francesco Guarascio

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.96% 7958 Delayed Quote.4.61%
MODERNA, INC. -3.01% 152.52 Delayed Quote.679.75%
PFIZER, INC. 0.62% 40.34 Delayed Quote.8.67%
SANOFI 0.69% 83.6 Real-time Quote.-6.72%
All news about ASTRAZENECA PLC
12:28aWALL STREET WEEK AHEAD : After blazing energy rally, investors check the fuel ga..
12/04With vaccines on the way, Mexico sees 'beginning of the end' of pandemic
12/04CANSINO BIOLOGICS : Mexico says COVID-19 vaccine deliveries could run through De..
12/04MODERNA : to supply 4 million more doses of COVID-19 vaccine to Israel
12/04FDA chief had 'robust discussion' with White House about vaccine timelines
12/04ASTRAZENECA : JP Morgan keeps its Buy rating
12/04Fortune or foresight? AstraZeneca and Oxford's stories clash on COVID-19 vacc..
12/03REUTERS SUMMIT-India's economy on the rebound, government focuses on spending..
12/03Canada could approve Pfizer's COVID-19 vaccine within the next week -official..
12/03India's economy on the rebound, government focuses on spending - finance mini..
More news
Financials (USD)
Sales 2020 26 494 M - -
Net income 2020 2 978 M - -
Net Debt 2020 13 237 M - -
P/E ratio 2020 45,2x
Yield 2020 2,63%
Capitalization 140 B 141 B -
EV / Sales 2020 5,80x
EV / Sales 2021 5,04x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 122,48 $
Last Close Price 106,93 $
Spread / Highest target 49,7%
Spread / Average Target 14,5%
Spread / Lowest Target -38,3%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.02%395 592
ROCHE HOLDING AG-3.74%290 107
PFIZER, INC.2.96%224 226
MERCK & CO., INC.-9.91%207 311
NOVARTIS AG-11.64%207 247